Salute e Benessere
Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study Period (2020-2034) Fueled by Advances in Treatment and Growing Healthcare Investments | DelveInsight
Discover more about the mild traumatic brain injury treatment market @
The traumatic brain injury market dynamics are expected to change in the coming years. Decades of innovation have led to like modern CT scanners and MRI machines, which can detect neuro-traumatic disorders more providing critical information in the vital hours after injury.
In 2024, became the , setting a clinical and regulatory precedent that strengthens the market and opens . With as a chronic health condition, particularly in moderate-to-severe cases, there is increasing focus on therapies that address its long-term effects, creating significant to capture market share and shape the future of TBI treatment. AKUUGO has received multiple regulatory designations, including Sakigake designation ( April 2019 ) and priority review designation ( January 2022 ) from Japan's MHLW, orphan regenerative medicine designation ( June 2020 ) from MHLW, RMAT designation ( September 2019 ) from the US FDA, and ATMP designation ( April 2019 ) from the EMA, recognizing its potential in treating chronic traumatic brain injury.
Furthermore, potential therapies are being investigated for the treatment of traumatic brain injury, and it is safe to predict that the treatment space will significantly impact the traumatic brain injury market during the forecast period. Moreover, increased , with improved efficacy, and a further are expected to drive the growth of the traumatic brain injury market in the 7MM. Most people ( ) suffer a mild TBI and on civilian, athlete, and military populations become increasingly apparent. Working together, developers, investors, and academic researchers are making progress in creating efficient medication solutions and addressing this unmet medical need. At present, drug development for concussions (mild TBI) is at an exciting moment, as several key players are targeting this untapped segment of TBI.
However, several factors may impede the growth of the traumatic brain injury market. As many as 30% of concussion patients experience persistent post-concussion symptoms and long-term effects—a than one might expect, especially given the within the medical community. Despite this, there are currently , with rest and gradual return to activity remaining the standard of care.
However, the development of new treatments is hindered by , which can stifle innovation. Moreover, the in TBI management , complicating patient care and driving up healthcare costs.
Furthermore, traumatic brain injury treatment poses a and disrupts patients' overall well-being and quality of life (QoL). Furthermore, the traumatic brain injury market growth may be offset by , (especially for cell therapies), , and l to the prescribed therapies. In addition, the about the disease may also impact the traumatic brain injury market growth.
Managing medications for individuals with traumatic brain injury is both complex and rewarding. These challenges are unsurprising given the intricacies of the brain and the many aspects that remain poorly understood. Although there are foundational principles that guide medication use, implementing them has become increasingly difficult due to systemic healthcare constraints, especially those related to reimbursement policies and rehabilitation timelines. Nonetheless, maintaining these principles is essential.
TBI treatment involves a combination of medical interventions, rehabilitation, and ongoing support, with approaches tailored to the severity of the injury. This can range from cognitive therapies to surgical procedures such as bilateral decompressive craniotomies. While clinical guidelines provide a framework, they must be individualized for each patient. Currently, treatment often depends on off-label use of various drug classes targeting symptom management, though these approaches frequently face high discontinuation rates. In response to these challenges, numerous companies are actively pursuing more effective therapeutic options to improve outcomes for individuals with TBI.
One notable advancement occurred in July 2024 , when became the first brain regeneration therapy to receive conditional approval in Japan . This allogeneic cell therapy is intended for patients with chronic motor paralysis resulting from TBI. The company plans to conduct a post-marketing study during the seven-year approval period and aims to , with intentions to pursue Phase III trials in discussions with the US FDA (Food and Drug Administration) and the EMA (European Medicines Agency).
To know more about FDA-approved drugs for traumatic brain injury, visit @
Some of the drugs in the pipeline include (Oxeia Biopharmaceuticals), (Hope Biosciences), (Oragenics), (Cellvation), (SHINKEI Therapeutics), and others.
is a synthetic version of human ghrelin, a naturally occurring hormone. It can easily cross the blood–brain barrier and plays a role in restoring metabolic and energy imbalances in the brain following a concussion. OXE103 specifically targets the hippocampus, a brain region critical for memory and cognitive function.
In February 2025 , the company announced plans to begin Phase IIb clinical trials for OXE103 later in the year. In June 2024 , Oxeia Biopharmaceuticals shared that findings from a study conducted at the University of Kansas Medical Center , examining OXE103's effectiveness in treating subacute concussion, were published in the April issue of Archives of Physical Medicine and Rehabilitation, a journal of the ACRM.
are mesenchymal stem cells derived from adipose (fat) tissue and developed using proprietary culturing technology. The company specializes in the culturing and banking of stem cells.
In June 2023 , UTHealth Houston received a nearly USD 5 million , four-year clinical trial grant from the Department of Defense's CDMRP to study whether intravenous administration of Hope Biosciences' autologous HB-adMSCs can reduce chronic neuroinflammation in patients with severe traumatic brain injury (TBI).
In May 2023 , preliminary data from a prior Phase I/IIa study involving 24 patients (NCT04063215), sponsored by UTHealth, were presented at the 2023 Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference in Scottsdale, Arizona .
is a novel, first-in-class enantiomeric neurosteroid in development for mild traumatic brain injury (mTBI), such as concussion. Its intellectual property covers its molecular structure, synthesis, and therapeutic applications. In preclinical models, ONP-002 has shown rapid molecular and behavioral improvements following neuronal injury.
In March 2025 , Oragenics announced it had submitted an Investigator's Brochure (IB) in preparation for a Phase II clinical trial of ONP-002 in Australia . This step marks significant progress in developing this intranasal neurosteroid as a treatment for mTBI. A proof-of-concept Phase IIb trial is also planned (third quarter of 2025) in the U.S. under an open Investigational New Drug (IND) approved by the FDA.
The anticipated launch of these emerging therapies are poised to transform the traumatic brain injury market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the traumatic brain injury market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about traumatic brain injury drugs in development @
Traumatic brain injury (TBI) occurs when the brain is suddenly harmed due to a blow or jolt to the head. It often results from incidents such as vehicle collisions, falls, sports-related accidents, or violent assaults. The severity of injury can vary widely, from minor concussions to severe, lasting brain damage. The initial damage sustained at the moment of impact is referred to as the primary injury, which can affect either a specific region of the brain or the entire organ. While a skull fracture might be present, it's not always the case. During a traumatic event, the brain can move forcefully within the skull, leading to bruising, bleeding, or tearing of nerve tissue.
TBI symptoms can be mild, moderate, or severe, depending on the extent of the brain injury. Someone with a mild TBI might stay conscious or briefly lose consciousness for just a few seconds or minutes. Other signs of mild TBI can include headache, dizziness, confusion, blurred or fatigued vision, ringing in the ears, unusual taste in the mouth, tiredness, changes in sleep, mood, or behavior shifts, and difficulties with memory, attention, or thinking.
. Instead, doctors evaluate the injury through a combination of medical history, symptoms, physical examination, and imaging studies like neuroimaging. Many individuals with TBI lose consciousness at the time of injury—this may last from mere seconds to minutes, although in severe cases, it can extend to days or even longer. Not all mild TBI cases involve loss of consciousness, but many individuals experience some degree of memory loss around the time of the trauma, which can last from minutes to hours or more.
The traumatic brain injury epidemiology section provides insights into the historical and current traumatic brain injury patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The traumatic brain injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand the traumatic brain injury assessment & management devices market @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TBI companies, including among others.
report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key traumatic brain injury assessment devices companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/traumatic-brain-injury-market-to-expand-at-a-cagr-of-10-9-during-the-study-period-20202034-fueled-by-advances-in-treatment-and-growing-healthcare-investments--delveinsight-302498620.html